A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 17 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • In the media
  • Voluntary Limits on Antibacterial Discharges...
Media - published on 22 Nov 2021
Share

Voluntary Limits on Antibacterial Discharges Increase As Fear of Resistance Grows

Shannon Brown writes for Pink Sheet, part of the Informa Pharma Intelligence network, about the AMR Benchmark's findings on manufacturing waste

Explore further

Setting standards with suppliers

Which companies require their suppliers to set discharge limits?

If manufacturing sites do not dispose of their antibacterial waste appropriately, this can lead to the development of resistant bacteria.
Manufacturing

Reported compliance with limits lags behind, especially at suppliers’ sites

Waste discharge limits may be increasingly mandatory, but many sites across the suppliers' side of the industry are not meeting them
Media

Millions Miss Out on Antibiotics in Echo of Vaccine Inequity

James Paton writes for Bloomberg Health about the findings of the 2021 Antimicrobial Resistance Benchmark.

Get in touch

  • Martijn van Gerven

    Martijn van Gerven

    Researcher

Back to top |